Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals (VRTX) shares rose 2.45% to $528.19 on Tuesday, outperforming the broader market which saw declines in the S&P 500 and Dow Jones. This marks two consecutive days of gains for VRTX, though it remains 3.29% below its 52-week high. Trading volume was slightly below the 50-day average. Compared to competitors, Vertex underperformed AbbVie but outperformed Krystal Biotech and Arcturus Therapeutics.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) rallied 2.45% to $528.19 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.69% to 7,691.76 and Dow Jones Industrial Average falling 0.22% to 53,343.40.
This was the stock's second consecutive day of gains.
Vertex Pharmaceuticals Inc. closed 3.29% short of its 52-week high of $546.17, which the company reached on August 10th.
The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as AbbVie Inc. (ABBV) rose 3.43% to $258.92, Krystal Biotech Inc. (KRYS) fell 0.87% to $332.82, and Arcturus Therapeutics Holdings Inc. (ARCT) rose 0.86% to $8.21.
Trading volume (1.5 M) remained 109,262 below its 50-day average volume of 1.6 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 18, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-18-26 1637ET